Advantages of antibodies in a complex (AAC)

AAC technology is based on the binding of limited amount of specific neutralizing antibodies to the target antigen (live or attenuated live virus or bacteria) prior to administration. The novel vaccine is then administered as an antigen-antibody entity, rather than antigen alone. Proper antigen presentation and processing is the key to successful vaccination. It is expected that antigens presented in the context of antibody will engage all immuoncytes with Fc binding capabilities (for conventional antigen presentation). The outcome of such involvement is expected to be superior to conventional presentation of vaccine antigens:

Improved vaccine efficacy:

• Enhanced immune responses from mild or highly attenuated vaccines
• Better presentation / processing of antigens
• Increased duration of immunity
• Effective, early vaccination in the face of maternal antibodies

Heightened vaccine safety:

• Reduced number of adverse effects (both morbidity and mortality) from live antigen vaccines
• Accommodation of more immunogenic strains of virus or bacteria
• Minimized or eliminated need for adjuvants

Extended vaccine utility:

• Reduced dosing schedule – single dose efficacy in many cases
• Added flexibility in the timing of vaccination
• Cross-protection to other strains of virus